BlackRock Inc. - INOZYME PHARMA INC ownership

INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 55 filers reported holding INOZYME PHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of INOZYME PHARMA INC
ValueSharesWeighting
Q3 2023$9,406,916
-12.9%
2,239,742
+15.5%
0.00%
Q2 2023$10,803,906
+317.9%
1,939,660
+329.9%
0.00%
Q1 2023$2,585,335
+477.7%
451,193
+5.9%
0.00%
Q4 2022$447,535
-61.0%
426,224
-0.5%
0.00%
Q3 2022$1,148,000
-44.1%
428,431
-0.5%
0.00%
Q2 2022$2,054,000
-42.8%
430,520
-51.0%
0.00%
Q1 2022$3,593,000
-37.1%
878,400
+4.9%
0.00%
Q4 2021$5,708,000
-45.3%
836,998
-7.1%
0.00%
Q3 2021$10,439,000
-31.9%
900,719
+0.1%
0.00%
Q2 2021$15,335,000
-10.1%
899,873
+4.4%
0.00%
-100.0%
Q1 2021$17,061,000
+31.1%
861,683
+36.6%
0.00%
Q4 2020$13,018,000
-1.1%
630,751
+25.9%
0.00%
Q3 2020$13,169,000500,9340.00%
Other shareholders
INOZYME PHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Pivotal bioVenture Partners Investment Advisor LLC 4,494,851$18,878,3747.53%
CHI Advisors LLC 1,270,027$5,334,1122.11%
Samsara BioCapital, LLC 1,562,500$6,562,5002.01%
Affinity Asset Advisors, LLC 1,379,852$5,795,3781.63%
Sofinnova Investments, Inc. 4,280,308$17,977,2941.13%
SPHERA FUNDS MANAGEMENT LTD. 1,234,907$5,186,6090.94%
Octagon Capital Advisors LP 1,300,000$5,460,0000.84%
NEA Management Company, LLC 2,437,689$10,238,2940.79%
Knott David M Jr 454,008$1,9070.73%
Rock Springs Capital Management LP 3,681,174$15,460,9310.41%
View complete list of INOZYME PHARMA INC shareholders